Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2017

Open Access 01-12-2017 | Study protocol

Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial

Authors: Ted A. Skolarus, Tabitha Metreger, Soohyun Hwang, Hyungjin Myra Kim, Robert L. Grubb III, Jeffrey R. Gingrich, Sarah T. Hawley

Published in: Trials | Issue 1/2017

Login to get access

Abstract

Background

Although prostate cancer is the most common cancer among veterans receiving care in the Veterans Health Administration (VA), more needs to be done to understand and improve survivorship care for this large population. This study, funded by VA Health Services Research & Development (HSR&D), seeks to address the need to improve patient-centered survivorship care for veterans with prostate cancer.

Methods/Design

This is a two-armed randomized controlled trial (RCT) with a target enrollment of up to 325 prostate cancer survivors per study arm (total anticipated n = 600). Patients will be recruited from four VA sites. Patient eligibility criteria include age range of 40–80 years, one to ten years post-treatment, and currently experiencing prostate cancer symptom burden. We will compare the “Building Your New Normal” program, a personally-tailored automated telephone symptom management intervention for improving symptom self-management to usual care enhanced with a non-tailored newsletter about symptom management. Primary outcomes include changes in symptom burden, bother, and health services utilization at five and 12 months after enrollment. Secondary outcomes include long-term psychosocial outcomes (e.g. subjective health, perceived cancer control). We will use multivariable regression analysis to evaluate the impact of the intervention on primary and secondary outcomes. We will conduct a process evaluation to understand the effective intervention components and explore possibilities for broader implementation and dissemination.

Discussion

Our central hypothesis is that intervention group participants will have improved and more confident symptom self-management and prostate cancer quality of life following the intervention and that these outcomes will translate to more efficient use of health services. The study results will provide much needed information about how to optimize the quality of care, and life, of veteran prostate cancer survivors.

Trial registration

ClinicalTrials.gov ID NCT01900561; Registered on 22 July 2013.
Appendix
Available only for authorised users
Literature
1.
Zullig LL, Jackson GL, Dorn RA, Provenzale DT, McNeil R, Thomas CM, et al. Cancer incidence among patients of the U.S Veterans Affairs Health Care System. Mil Med. 2012;177(6):693–701.PubMedPubMedCentralCrossRef
2.
Robinson LL, Demark-Wahnefried W. Cancer survivorship: focusing on future research opportunities. Cancer Epidemiol Biomarkers Prev. 2011;20(10):1994–5.CrossRef
3.
Wilt TJ, Shamliyan TA, Taylor BC, McDonald R, Kane RL. Association between hospital and surgeon radical prostatectomy volume and patient outcomes: a systematic review. J Urol. 2008;180(3):820–8. discussion 828–829.PubMedCrossRef
4.
Skolarus TA, Miller DC, Zhang Y, Hollingsworth JM, Hollenbeck BK. The delivery of prostate cancer care in the United States: implications for delivery system reform. J Urol. 2010;184(6):2279–84.PubMedCrossRef
5.
Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977–84.PubMedCrossRef
6.
Watson E, Shinkins B, Frith E, Neal D, Hamdy F, Walter F, Weller D, Wilkinson C, Faithfull S, Wolstenholme J, Sooriakumaran P, Kastner C, Campbell C, Neal R, Butcher H, Matthews M, Perera R, Rose P. Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. BJU Int. 2016;117(6B):E10–9. doi:10.​1111/​bju.​13122. Epub 2015 May 23.
7.
Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011;306(11):1205–14.PubMedCrossRef
8.
Dandapani SV, Sanda MG. Measuring health-related quality of life consequences from primary treatment for early-state prostate cancer. Semin Radiat Oncol. 2008;18(1):67–72.PubMedPubMedCentralCrossRef
9.
Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M, et al. Long-term quality of life outcomes after radical prostatectomy or watchful waiting: The Scandinavian Prostate Cancer Group-4 randomized trial. Lancet Oncol. 2011;12(9):891–9.PubMedCrossRef
10.
Johansson E, Bill-Axelson A, Holmberg L, Onelov E, Johansson JE, Steineck G, et al. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol. 2009;55(2):422–30.PubMedCrossRef
11.
Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347(11):790–6.PubMedCrossRef
12.
Penson DF, Litwin MS. Quality of life after treatment for prostate cancer. Curr Urol Rep. 2003;4(3):185–95.PubMedCrossRef
13.
Kerleau C, Guizard AV, Daubisse-Marliac L, Heutte N, Mercier M, Grosclaude P, Joly F; French Network of Cancer Registries (FRANCIM). Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study. Eur J Cancer. 2016;63:143–53. doi:10.​1016/​j.​ejca.​2016.​05.​020. Epub 2016 Jun 15.
14.
Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009;101(12):888–92.PubMedCrossRef
15.
Hoffman RM, MacDonald R, Wilt TJ. Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev. 2004;1:CD001987.
16.
Reeve BB, Stover AM, Jensen RE, Chen RC, Taylor KL, Clauser SB, et al. Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: a population-based study. Cancer. 2012;118(22):5679–87.PubMedPubMedCentralCrossRef
17.
Ferrer M, Suarez JF, Guedea F, Fernandez P, Macias V, Marino A, et al. Health-related quality of life two years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(2):421–32.PubMedCrossRef
18.
Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92(19):1582–92.PubMedCrossRef
19.
Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358–67.PubMedCrossRef
20.
Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20(2):557–66.PubMedCrossRef
21.
Harrington CB, Hansen JA, Moskowitz M, Todd BL, Feuerstein M. It’s not over when it’s over: long-term symptoms in cancer survivors -- a systematic review. J Psychiatry Med. 2010;40(2):163–81.CrossRef
22.
Wei JT, Dunn RL, Marcovich R, Montie JE, Sanda MG. Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol. 2000;164(3 Pt 1):744–8.PubMedCrossRef
23.
Miller DC, Wei JT, Dunn RL, Montie JE, Pimentel H, Sandler HM, et al. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. Urology. 2006;68(1):166–71.PubMedCrossRef
24.
Taylor KL, Luta G, Miller AB, Church TR, Kelly SP, Muenz LR, et al. Long-term disease-specific functioning among prostate cancer survivors and non-cancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2012;30(22):2768–75.PubMedPubMedCentralCrossRef
25.
Pardo Y, Guedea F, Aguilo F, Fernandez P, Macias V, Marino A, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010;28(31):4687–96.PubMedCrossRef
26.
Clark JA, Rieker P, Propert KJ, Talcott JA. Changes in quality of life following treatment for early prostate cancer. Urology. 1999;53:161–8.PubMedCrossRef
27.
Clark JA, Talcott JA. Confidence and uncertainty long after initial treatment for early prostate cancer: survivors’ views of cancer control and the treatment decisions they made. J Clin Oncol. 2006;24(27):4457–63.PubMedCrossRef
28.
Clark JA, Inui TS, Silliman RA, Bokhour BG, Krasnow SH, Robinson RA, et al. Patients’ perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol. 2003;21(20):3777–84.PubMedCrossRef
29.
Messer KL, Hines SH, Raghunathan TE, Seng JS, Diokno AC, et al. Self-efficacy as a predictor to PFMT adherence in a prevention of urinary incontinence clinical trial. Health Educ Behav. 2007;34(6):942–52.PubMedCrossRef
30.
Zhang AY, Fu AZ, Moore S, Zhu H, Strauss G, Kresevic D, Klein E, Ponsky L, Bodner DR. Is a behavioral treatment for urinary incontinence beneficial to prostate cancer survivors as a follow-up care? J Cancer Surviv. 2017;11(1):24–31. doi:10.​1007/​s11764-016-0557-0. Epub 2016 Jun 24.
31.
Ribeiro LH, Prota C, Gomes CM, de Bessa Jr J, Boldarine MP, Dall’Oglio MF, et al. Long-term effect of early postoperative pelvic floor biofeedback on continence in men undergoing radical prostatectomy: a prospective, randomized, controlled trial. J Urol. 2010;184(3):1034–9.PubMedCrossRef
32.
Hunter KF, Glazener CM, Moore KN. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev. 2007;2:CD001843.
33.
Dougherty MC, Dwyer JW, Pendergast JF, Boyington AR, Tomlinson BU, Coward RT, et al. A randomized trial of behavioral management for continence with older rural women. Res Nurs Health. 2002;25(1):3–13.PubMedCrossRef
34.
Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev (Online). 2004;(1):CD001308.
35.
Milne JL. Behavioral therapies at the primary care level: the current state of knowledge. J Wound Ostomy Cont Nurs. 2004;31(6):367–76. quiz 377-368.CrossRef
36.
Wolin K, Luly J, Sutcliffe S, Andriole G, Kibel A. Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol. 2010;183(2):629–33.PubMedCrossRef
37.
Subak LL, Johnson C, Whitcomb E, Boban D, Saxton J, Brown JS. Does weight loss improve incontinence in moderately obese women? Int Urogynecol J Pelvic Floor Dysfunct. 2002;13(1):40–3.PubMedCrossRef
38.
Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstet Gynecol. 2000;96(1):85–9.PubMed
39.
Campbell SE, Glazener CM, Hunter KF, Cody JD, Moore KN. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev (Online). 2012;1:CD001843.
40.
Fader M, Cottenden A, Getliffe K, Gage H, Clarke-O’Neill S, Jamieson K, et al. Absorbent products for urinary/faecal incontinence: a comparative evaluation of key product designs. Health Technol Assess. 2008;12(29):iii–iv. ix-185.PubMedCrossRef
41.
Manne SL, Kissane DW, Nelson CJ, Mulhall JP, Winkel G, Zaider T. Intimacy-enhancing psychological intervention for men diagnosed with prostate cancer and their partners: a pilot study. J Sex Med. 2011;8(4):1197–209.PubMedPubMedCentralCrossRef
42.
Manne S. Restoring intimacy in relationships affected by cancer. In: Mulhall JP, Incrocci L, Goldstein I, Rosen R, editors. Cancer and Sexual Health. New York: Springer; 2011. p. 739–50.CrossRef
43.
Manne S, Kissane D, Zaider T, Nelson C, Winkel G. Intimacy-enhancing intervention for couples coping with localized prostate cancer. Ann Behav Med. 2010;39:116.
44.
Brotto LA, Yule M, Breckon E. Psychological interventions for the sexual sequelae of cancer: a review of the literature. J Cancer Surviv. 2010;4(4):346–60.PubMedCrossRef
45.
46.
Manne S, Ostroff J, Rini C, et al. The interpersonal process model of intimacy: The role of self-disclosure, partner disclosure, and partner responsiveness in interactions between breast cancer patients and their partners. J Fam Psychol. 2004;18(4):589–99.PubMedCrossRef
47.
Mehta A, Deveci S, Mulhall JP. Efficacy of a penile variable tension loop for improving climacturia after radical prostatectomy. BJU Int. 2013;111(3):500–4.PubMedCrossRef
48.
49.
Sighinolfi MC, Rivalta M, Mofferdin A, Micali S, De Stefani S, Bianchi G. Potential effectiveness of pelvic floor rehabilitation treatment for postradical prostatectomy incontinence, climacturia, and erectile dysfunction: a case series. J Sex Med. 2009;6(12):3496–9.PubMedCrossRef
50.
Harte CB, Meston CM. Association between smoking cessation and sexual health in men. BJU Int. 2012;109(6):888–96.PubMedCrossRef
51.
Meldrum DR, Gambone JC, Morris MA, Esposito K, Giugliano D, Ignarro LJ. Lifestyle and metabolic approaches to maximizing erectile and vascular health. Int J Impot Res. 2012;24(2):61–8.PubMedCrossRef
52.
Engel JD. Effect on sexual functoin of a vacuum erection device post-prostatectomy. Can J Urol. 2011;18(3):5721–5.PubMed
53.
Raina R, Pahlajani G, Agarwal A, Jones S, Zippe C. Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU Int. 2010;106(11):1719–22.PubMedCrossRef
54.
Dalkin BL, Christopher BA. Preservation of penile length after radical prostatectomy: early intervention with a vacuum erection device. Int J Impot Res. 2007;19(5):501–4.PubMedCrossRef
55.
Hellstrom WJ, Montague DK, Moncada I, Carson C, Minhas S, Faria G, et al. Implants, mechanical devices, and vascular surgery for erectile dysfunction. J Sex Med. 2010;7(1 (Part 2)):501–23.PubMedCrossRef
56.
Norton C, Cody JD. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database Syst Rev. 2012;7:CD002111.
57.
Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012;8:CD008465.
58.
Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer. 2012;21(1):313–26.PubMedCrossRef
59.
Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62(6):591–9.PubMed
60.
Savard J, Hervouet S, Ivers H. Prostate cancer treatments and their side effects are associated with increased insomnia. Psychooncology. 2013;22(6):1381–8.PubMedCrossRef
61.
Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21(9):1653–9.PubMedCrossRef
62.
Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer. 2011;105 Suppl 1:S52–73.PubMedPubMedCentralCrossRef
63.
64.
Foster C, Fenion D. Recovery and self-management support following primary cancer treatment. Br J Cancer. 2011;105L:S21–8.CrossRef
65.
Bandura A. Self-efficacy mechanism in human agency. Am Psychol. 1982;37(2):122–47.CrossRef
66.
Bandura A. Social Learning Theory. Prentice Hall: Englewood Cliffs; 1977.
67.
Torbit LA, Albiani JJ, Crangle CJ, Latini DM, Hart TL. Fear of recurrence: The importance of self-efficacy and satisfaction with care in gay men with prostate cancer. Psychooncology. 2015;24:691–8.PubMedCrossRef
68.
Anderson M, Funnell MM. Empowerment and self-management of diabetes. Clin Diab. 2004;22(3):123–7.CrossRef
69.
Arnold MS, Butler PM, Anderson RM, Funnell MM, Feste C. Guidelines for facilitating a patient empowerment program. Diabetes Educ. 1995;21:308–12.PubMedCrossRef
70.
Turk DC, Meichenbaum D, Genest M. Pain and behavioral medicine: a cognitive behavioral approach. NY: Guilford Press; 1983.
71.
Piette JD, Richardson C, Himle J, Duffy S, Torres T, Vogel M, et al. A randomized trial of telephonic counseling plus walking for depressed diabetes patients. Med Care. 2011;49(7):641–8.PubMedPubMedCentralCrossRef
72.
Piette JD. Use of CBT in a walking program for veterans with diabetes and depression. Psychiatr Serv. 2005;56(3):355.PubMedCrossRef
73.
Price JR, Couper J. Cognitive behavior therapy for adults with chronic fatigue syndrome. Cochrane Database Syst Rev. 2000;2:CD001027.
74.
Baumann FT, Zoph EM, Bloch W. Clinical exercise interventions in prostate cancer patients -- a systematic review of randomized controlled trials. Support Care Cancer. 2011;20(2):221–33.PubMedCrossRef
75.
Goode PS, Burgio KL, Johnson 2nd TM, Clay OJ, Roth DL, Markland AD, et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence. JAMA. 2011;305(2):151–9.PubMedCrossRef
76.
Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29(6):726–32.PubMedPubMedCentralCrossRef
77.
Meldrum DR, Gambone JC, Morris MA, Ignarro LJ. A multifaceted approach to maximize erectile function and vascular health. Fertil Steril. 2010;94(7):2514–20.PubMedCrossRef
78.
79.
80.
Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011;186(3):865–72.PubMedCrossRef
81.
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.PubMedCrossRef
82.
Wei JT, Montie JE. Comparison of patients’ and physicians’ rating of urinary incontinence following radical prostatectomy. Semin Urol Oncol. 2000;18(1):76–80.PubMed
83.
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, et al. Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med. 2008;358:1250–61.PubMedCrossRef
84.
Dunn RL, Sanda MG, Wei JT. Minimally important difference for the Expanded Prostate Cancer Index Composite (EPIC). New Orleans: International Society for Quality of Life Research; 2009. p. A-98.
85.
Maly RC, Frank JC, Marshall GN, DiMatteo MR, Reuben DB. Perceived efficacy in patient–physician interactions (PEPPI): validation of an instrument in older persons. J Am Geriatr Soc. 1998;46:889–94.PubMedCrossRef
86.
Carver CS. You want to measure coping but your protocol’s too long: Consider the Brief COPE. Int J Behav Med. 1997;4:92–100.PubMedCrossRef
87.
Skolarus TA, Wittmann D, Northouse L, An LC, Olson KG, Rew K, et al. Recommendations for prostate cancer survivorship care: an update to the 2009 Michigan Cancer Consortium Guidelines for the Primary Care Management of Prostate Cancer Post-Treatment Sequelae. J Men's Health. 2014;11(3):95–107.CrossRef
88.
Greenfield S, Cretin S, Worthman LG, Dorey FJ, Soloman NE, Goldberg GA. Comparison of a criteria map to a criteria list in quality-of-care assessment for patients with chest pain: the relation of each to outcome. Med Care. 1981;19(3):255–72.PubMedCrossRef
89.
Greenfield S, Worthman LG, Cretin S. Quality assessment by the criteria mapping method. Top Health Rec Manage. 1980;1(2):37–44.PubMed
90.
Piette JD, Rosland AM, Marinec NS, Striplin D, Bernstein SJ, Silveira MJ. Engagement with automated patient monitoring and self-management support calls: experience with 1000 chronically ill patients. Med Care. 2013;51(3):216–23.PubMedPubMedCentralCrossRef
91.
Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000;21(3):167–89.PubMedCrossRef
92.
Little R, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health. 2000;21(1):121–45.PubMedCrossRef
93.
Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217–26.PubMedPubMedCentralCrossRef
94.
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.PubMedPubMedCentralCrossRef
95.
Janz NK, Mujahid M, Chung LK, Lantz PM, Hawley ST, Morrow M, et al. Symptom experience and quality of life of women following breast cancer treatment. J Women's Health. 2007;16(9):1348–61.CrossRef
Metadata
Title
Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial
Authors
Ted A. Skolarus
Tabitha Metreger
Soohyun Hwang
Hyungjin Myra Kim
Robert L. Grubb III
Jeffrey R. Gingrich
Sarah T. Hawley
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Trials / Issue 1/2017
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-017-1925-4

Other articles of this Issue 1/2017

Trials 1/2017 Go to the issue

Study protocol

Retroclavicular approach vs infraclavicular approach for plexic bloc anesthesia of the upper limb: study protocol randomized controlled trial

Correction

Correction to: Anti-inflammatory and immune regulatory effects of acupuncture after craniotomy: study protocol for a parallel-group randomized controlled trial

Study protocol

Evaluating a multi-component, community-based program to improve adherence and retention in care among adolescents living with HIV in Zimbabwe: study protocol for a cluster randomized controlled trial

Study protocol

Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial

Research

The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials

Study protocol

Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study